Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C21H25N7O6.2Na |
| Molecular Weight | 517.446 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CN1C(CCNC2=CC=C(C=C2)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)CNC3=C1C(=O)N=C(N)N3
InChI
InChIKey=PASPSZYIMAFFFK-HNYZGNTBSA-L
InChI=1S/C21H27N7O6.2Na/c1-28-13(10-24-17-16(28)19(32)27-21(22)26-17)8-9-23-12-4-2-11(3-5-12)18(31)25-14(20(33)34)6-7-15(29)30;;/h2-5,13-14,23H,6-10H2,1H3,(H,25,31)(H,29,30)(H,33,34)(H4,22,24,26,27,32);;/q;2*+1/p-2/t13?,14-;;/m0../s1
KETOTREXATE is an antifolate developed to overcome methotrexate (MTX) resistance. However, it demonstrated such potential only in MTX-resistant sensitive L1210/FR8 leukemia cells and its clinical development was discontinued. Unlike MTX, KETOTREXATE exhibited minimal inhibition of purified dihydrofolate reductase, which implies that it does not act as a classical antifolate.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
129MT3SP3E
Created by
admin on Fri Dec 15 15:23:42 GMT 2023 , Edited by admin on Fri Dec 15 15:23:42 GMT 2023
|
PRIMARY | |||
|
139490
Created by
admin on Fri Dec 15 15:23:42 GMT 2023 , Edited by admin on Fri Dec 15 15:23:42 GMT 2023
|
PRIMARY | |||
|
52386-42-2
Created by
admin on Fri Dec 15 15:23:42 GMT 2023 , Edited by admin on Fri Dec 15 15:23:42 GMT 2023
|
PRIMARY | |||
|
135475347
Created by
admin on Fri Dec 15 15:23:42 GMT 2023 , Edited by admin on Fri Dec 15 15:23:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
